- Trials with a EudraCT protocol (66)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
66 result(s) found for: Chromosome 17.
Displaying page 1 of 4.
EudraCT Number: 2007-000208-34 | Sponsor Protocol Number: CAMN107A2303 | Start Date*: 2007-06-11 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: A phase III multi-center, open label, randomised study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chr... | ||||||||||||||||||
Medical condition: Adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) CZ (Completed) BE (Completed) IT (Completed) ES (Completed) SK (Completed) AT (Completed) FR (Completed) NL (Completed) FI (Completed) DK (Completed) DE (Completed) PT (Prematurely Ended) HU (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-017775-19 | Sponsor Protocol Number: CAMN107EIC01 | Start Date*: 2010-05-07 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase | |||||||||||||
Medical condition: Newly diagnosed Philadelphia chromosome and/or BCR-ABL positive chronic myeloid leukaemia (CML) in chronic phase in adult patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NL (Completed) BE (Completed) HU (Completed) ES (Completed) FI (Completed) GB (Completed) PT (Completed) DE (Completed) SE (Completed) CZ (Completed) DK (Completed) SK (Completed) GR (Completed) AT (Completed) LT (Completed) IT (Completed) LV (Completed) SI (Completed) EE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005694-21 | Sponsor Protocol Number: EWALL-PH-01 (Graalphag06) | Start Date*: 2007-06-29 |
Sponsor Name:CH-Versailles | ||
Full Title: AN OPEN LABEL PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INDUCTION AND CONSOLIDATION THERAPY WITH DASATINIB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS AGED 55 YEARS AND OVER WITH PHIL... | ||
Medical condition: Philadelphia chromosome positive Acute Lymphoblastic Leukemia | ||
Disease: | ||
Population Age: | Gender: Male, Female | |
Trial protocol: FR (Completed) DE (Completed) BE (Completed) IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000251-89 | Sponsor Protocol Number: 1042-0800 | Start Date*: 2014-10-22 | |||||||||||
Sponsor Name:Antwerp University Hospital | |||||||||||||
Full Title: A controlled double-blind crossover trial of ganaxolone in children with fragile X syndrome | |||||||||||||
Medical condition: behavioral problems in children with fragile X syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002485-39 | Sponsor Protocol Number: TAK-935-18-001(OV935)Amendment1 | Start Date*: 2019-06-14 |
Sponsor Name:Ovid Therapeutics, Inc. | ||
Full Title: A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEP... | ||
Medical condition: developmental and epileptic encephalopathies | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) PL (Trial now transitioned) PT (Trial now transitioned) Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2014-002476-92 | Sponsor Protocol Number: 20120215 | Start Date*: 2015-06-29 | |||||||||||||||||||||
Sponsor Name:Amgen Inc | |||||||||||||||||||||||
Full Title: A Randomized, Open-label, Controlled Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidatio... | |||||||||||||||||||||||
Medical condition: Patients with Philadelphia chromosome negative (Ph-) high-risk (HR) first relapse B-precursor ALL (as defined by I-BFM SG/IntReALL criteria) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) CZ (Completed) BE (Completed) IT (Completed) SE (Completed) PT (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Ongoing) FR (Completed) NL (Completed) Outside EU/EEA GR (Completed) NO (Completed) HU (Completed) RO (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-001539-31 | Sponsor Protocol Number: FE999905 CS002 | Start Date*: 2005-09-16 |
Sponsor Name:Ferring Pharmaceuticals A/S | ||
Full Title: An Open-label, Multi-centre, Phase III Study of Local Tolerability of Zomacton 10 mg (Recombinant Somatropin) administered by ZomaJet Vision X | ||
Medical condition: Zomacton is indicated for the long term treatment of children who have growth failure due to inadequate secretion of growth hormone and for the long-term treatment of growth retardation due to Turn... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000678-27 | Sponsor Protocol Number: CABL001J12301 | Start Date*: 2021-08-10 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leuk... | |||||||||||||
Medical condition: Chronic Myelogenous Leukemia in chronic phase (CML-CP) in newly diagnosed patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) SK (Trial now transitioned) SE (Trial now transitioned) AT (Ongoing) NO (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) FI (Trial now transitioned) NL (Completed) DK (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022638-96 | Sponsor Protocol Number: CAFQ056B2214 | Start Date*: 2011-06-15 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of AFQ056 in adolescent patients with Fragile X Syndrome | |||||||||||||
Medical condition: Fragile X Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) FR (Completed) DK (Completed) DE (Completed) ES (Completed) Outside EU/EEA IT (Completed) BE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021790-37 | Sponsor Protocol Number: UK_S-H_08_0006 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Lübeck | |||||||||||||
Full Title: Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS) | |||||||||||||
Medical condition: The medical condition under investigation is complete androgen insensitivity syndrome (CAIS) in gonadectomized patients with 46,XY karyotype due to mutations of the androgen receptor, which lead to... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002916-34 | Sponsor Protocol Number: ITCC-054/AAML1921 | Start Date*: 2016-06-13 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: A Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic phase or resistant/intolerant Ph+ Chronic Myeloid Leukemia, study ITCC-054/COG AAML1921 | |||||||||||||
Medical condition: Chronic Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) IE (Completed) DE (Ongoing) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) DK (Completed) CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000705-20 | Sponsor Protocol Number: EsPhALL2017/COGAALL1631 | Start Date*: 2017-12-11 | ||||||||||||||||
Sponsor Name:Università degli Studi Milano Bicocca | ||||||||||||||||||
Full Title: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones | ||||||||||||||||||
Medical condition: Philadelphia positive Acute Lumphoblastic Leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003791-13 | Sponsor Protocol Number: BP42992 | Start Date*: 2022-01-11 | |||||||||||
Sponsor Name:F. HOFFMANN - LA ROCHE LTD. | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF 52 WEEKS OF TREATMENT WITH BASMISANIL IN CHILDREN WITH DUP15... | |||||||||||||
Medical condition: Dup15q Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) PL (Completed) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023111-34 | Sponsor Protocol Number: SG1/001/10 | Start Date*: 2011-07-18 |
Sponsor Name:Oxford BioMedica (UK) Ltd | ||
Full Title: A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected StarGen, Administered to Patients with Stargardt's Macular Degeneration. | ||
Medical condition: Stargardt Macular Dystrophy, also known as fundus flavimaculatus or Stargardt disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) NL (Not Authorised) IT (Prematurely Ended) Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2015-003667-11 | Sponsor Protocol Number: M15-550 | Start Date*: 2016-08-01 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: Open-Label, Single Arm, Phase 3B, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) (VENICE I) | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) SE (Completed) BE (Completed) NL (Completed) DE (Completed) AT (Completed) IE (Completed) PT (Completed) FI (Completed) DK (Completed) ES (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019577-16 | Sponsor Protocol Number: EGF114299 | Start Date*: 2010-12-21 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as first- or second-lin... | |||||||||||||
Medical condition: HER2-positive metastatic breast cancer who have received prior trastuzumab and endocrine therapies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) HU (Completed) IE (Prematurely Ended) PL (Completed) BE (Completed) BG (Prematurely Ended) NO (Ongoing) GB (Completed) LT (Prematurely Ended) PT (Prematurely Ended) ES (Ongoing) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001850-80 | Sponsor Protocol Number: NLG-MCL8 | Start Date*: 2021-04-07 |
Sponsor Name:Skåne University Hospital | ||
Full Title: Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma | ||
Medical condition: Mantle Cell Lymphoma (MCL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001691-39 | Sponsor Protocol Number: UKM17_0023 | Start Date*: 2019-07-16 | |||||||||||
Sponsor Name:University Hospital Münster | |||||||||||||
Full Title: LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma | |||||||||||||
Medical condition: Lymphoblastic lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) DE (Ongoing) DK (Trial now transitioned) IE (Completed) NO (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) NL (Ongoing) SK (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001286-20 | Sponsor Protocol Number: CABL001I12201 | Start Date*: 2021-07-29 | |||||||||||||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||||||||||||
Full Title: A multi-center, open-label study to determine the dose and safety of oral asciminib in pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP... | |||||||||||||||||||||||
Medical condition: Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: HU (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002260-33 | Sponsor Protocol Number: CA180-226 | Start Date*: 2009-02-16 | |||||||||||
Sponsor Name:Bristol-Myers Squibb Internaltional Corporation | |||||||||||||
Full Title: A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or with Ph+ Leukemias Resistant or Intolerant to Imatinib Revised... | |||||||||||||
Medical condition: Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) ES (Ongoing) FR (Trial now transitioned) NL (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
